Nicardipine
As of the edition of 20 October 2026, Nicardipine is a small molecule: marketed, first approved in 1984 (ES); acts on CACNA1C, CACNA1D and CACNA1F and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Cardene
- First approved
- 1 January 1984 (ES)
- Approvals on record
- 16 in 3 regions
- Holder of the most recent approval
- Hikma International Pharmaceuticals; 5 holders in all
- Registered trials
- 26, 4 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Infections; Animal diseases; Chemically induced; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Nicardipine.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 6 | 4 | 0 |
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 4 | 2 | 0 | 2 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 7 | 2 | 2 | 0 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Dupont Merck | Later holder | 1992 to now |
| Teva | Later holder | 2008 to now |
| Chiesi | Acquired holder | 2014 to now |
| SUN Pharmaceutical Industries | Acquired holder | 2021 to now |
| Hikma International Pharmaceuticals | Acquired holder | 2022 to now |